IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways

Background: The efficacy of an EGFR-targeted treatment strategy for non-small cell lung cancer (NSCLC) is reduced by drug resistance. IL-22 enhances tumor growth and induces chemotherapy resistance in human lung cancer cells. The present study elucidated the IL-22-induced mechanism underlying EGFR-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaomeng, Xu, Jiali, Chen, Jin, Jin, Shidai, Yao, Jiaqi, Yu, Tongfu, Wang, Wei, Guo, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848259/
https://www.ncbi.nlm.nih.gov/pubmed/31750252
http://dx.doi.org/10.3389/fonc.2019.01167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848259/
https://www.ncbi.nlm.nih.gov/pubmed/31750252
http://dx.doi.org/10.3389/fonc.2019.01167

Ejemplares similares